Table 1.
Demographics of the prostate cancer population (n = 1114) that was treated with robot-assisted radical prostatectomy (RARP)
| Median (IQR) or frequency (%) | |
|---|---|
| Clinical factors | |
| Age (years) | 65 (61–70) |
| Body mass index, BMI (kg/m2) | 25.7 (23.9–28) |
| Prostate specific antigen, PSA (μg/L) | 7 (5.1–9.7) |
| Prostate volume, PV (mL) | 40 (30.3–52) |
| Biopsy positive cores, BPC (%) | 34.5 (21–53) |
| International Society of Urologic Pathology (ISUP) tumor grade system | |
| ISUP = 1 | 436 (39.1) |
| ISUP = 2 | 356 (32.0) |
| ISUP = 3 | 192 (17.2) |
| ISUP = 4 | 106 (9.5) |
| ISUP = 5 | 24 (2.2) |
| Tumor clinical stage (cT) | |
| cT1 | 687 (61.7) |
| cT2/3 | 427 (38.3) |
| Clinical nodal stage (cN) | |
| cN0 | 1058 (95) |
| cN1 | 56 (5) |
| American Society of Anesthesiologists’ (ASA) physical system | |
| ASA I | 104 (9.3) |
| ASA II | 905 (81.2) |
| ASA III | 105 (9.5) |
| D’Amico risk groups | |
| Low risk class | 305 (27.4) |
| Intermediate risk class | 590 (53.0) |
| High risk class | 219 (19.6) |
| Pathological factors | |
| Prostate weight; gr (PW) | 51 (42–65) |
| ISUP = 1 | 143 (12.8) |
| ISUP = 2 | 438 (39.3) |
| ISUP = 3 | 303 (27.2) |
| ISUP = 4 | 158 (14.2) |
| ISUP = 5 | 72 (6.5) |
| Pathological tumor stage (pT) | |
| pT2 | 874 (78.5) |
| pT3a | 109 (9.8) |
| pT3b | 131 (11.8) |
| Positive surgical margin (PSM) | |
| No | 843 (75.7) |
| Yes | 271 (24.3) |
| Pathological nodal staging (pN) | |
| pN0 | 599 (53.8) |
| pN1 | 79 (7.1) |
| pNx | 436 (39.1) |
| Lymph nodes removed (number) | 25 (20–32) |
| Perioperative factors | |
| High volume surgeon (HVS) | 600 (53.9) |
| Low volume surgeon (LVS) | 475 (42.6) |
| Unknown | 39 (3.5) |
| Operating time; min (OT) | 233 (205–259.3) |
| Blood lost; mL (BL) | 300 (150–400) |
| Any post-operative Clavien–Dindo complication at discharge (CDC) | 273 (24.5) |
| Length of hospital stay; days (LOHS) | 4 (4–5) |
| Hospital readmission; n (%) | 35 (3.1) |
IQR interquartile range, % percentage